Company intelligence / Profile preview

MeatAfora

Ownership: Private
Employees: ~12
Development stage: Preclinical

Overview

METAglut1™, their lead product, received CE marking in 2017, universal national coverage by French National Health Insurance as of February 2024, and has demonstrated clear clinical benefits in early detection of Glut1 Deficiency Syndrome. A large-scale clinical study (>30 centers) supported its efficacy. New assays in oncology are under development but not yet commercialized.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: In vitro diagnostics (IVD)Device (flow cytometry software)Reagent (cell therapy reagents)AI-powered data analysis platform
Industry: Protein Biomarker Diagnostics

Partnerships

Sebia – partnership to develop innovative IVDs for hemato-oncologycollaborations with leading medical researchers and patient associationsEIC Accelerator program laureateBpifrance Innovation Prize winner

Beyond the preview

Go deeper on MeatAfora.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MeatAfora.

Explore the full profile